Jorge Sérgio Reis‐filho
#93,696
Most Influential Person Now
Jorge Sérgio Reis‐filho's AcademicInfluence.com Rankings
Jorge Sérgio Reis‐filhophilosophy Degrees
Philosophy
#3496
World Rank
#5639
Historical Rank
Logic
#1195
World Rank
#1881
Historical Rank

Jorge Sérgio Reis‐filhobiology Degrees
Biology
#4385
World Rank
#6544
Historical Rank
Pathology
#47
World Rank
#107
Historical Rank

Download Badge
Philosophy Biology
Jorge Sérgio Reis‐filho's Degrees
- Doctorate Medicine University of Porto
- PhD Pathology University of Porto
Why Is Jorge Sérgio Reis‐filho Influential?
(Suggest an Edit or Addition)Jorge Sérgio Reis‐filho's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. (2015) (1875)
- International network of cancer genome projects (2010) (1839)
- Triple-negative breast cancer. (2010) (1781)
- The landscape of cancer genes and mutational processes in breast cancer (2012) (1610)
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF (2010) (1366)
- Resistance to therapy caused by intragenic deletion in BRCA2 (2008) (933)
- Triple negative tumours: a critical review (2007) (919)
- Basal-like breast cancer: a critical review. (2008) (910)
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer (2015) (844)
- COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES (2009) (839)
- Breast cancer prognostic classification in the molecular era: the role of histological grade (2010) (749)
- BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. (2010) (698)
- Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. (2014) (684)
- Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype (2005) (667)
- Gene expression profiling in breast cancer: classification, prognostication, and prediction (2011) (658)
- FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. (2010) (631)
- Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists (2011) (629)
- RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. (2012) (610)
- BRCA1 dysfunction in sporadic basal-like breast cancer (2007) (609)
- Oncogenic Braf induces melanocyte senescence and melanoma in mice. (2009) (534)
- Molecular evolution of breast cancer (2005) (532)
- Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma (2015) (523)
- Germline mutations in RAD51D confer susceptibility to ovarian cancer (2011) (493)
- Basal-like breast cancer and the BRCA1 phenotype (2006) (486)
- Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes (2009) (473)
- The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade (2010) (457)
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020) (432)
- Histological types of breast cancer: How special are they? (2010) (429)
- Histological and molecular types of breast cancer: is there a unifying taxonomy? (2009) (419)
- Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe (2017) (408)
- Genetic heterogeneity and cancer drug resistance. (2012) (398)
- Genetic Interactions in Cancer Progression and Treatment (2011) (397)
- High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants (2019) (397)
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets (2009) (385)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Breast cancer molecular profiling with single sample predictors: a retrospective analysis. (2010) (362)
- Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast (2006) (357)
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. (2018) (348)
- Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival (2007) (331)
- Functionally Recurrent Rearrangements of the MAST Kinase and Notch Gene Families in Breast Cancer (2011) (330)
- β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation (2011) (325)
- Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients (2008) (321)
- Breast cancer precursors revisited: molecular features and progression pathways (2010) (307)
- Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma (2011) (305)
- Phyllodes tumours of the breast: a consensus review (2016) (305)
- Basal-like breast carcinomas: clinical outcome and response to chemotherapy (2006) (297)
- Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor (2013) (291)
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer (2010) (288)
- Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. (2002) (284)
- FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas (2006) (280)
- FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis (2007) (273)
- Columnar Cell Lesions of the Breast: The Missing Link in Breast Cancer Progression?: A Morphological and Molecular Analysis (2005) (270)
- Breast cancer intra-tumor heterogeneity (2014) (258)
- High Frequency of Coexistence of Columnar Cell Lesions, Lobular Neoplasia, and Low Grade Ductal Carcinoma In Situ With Invasive Tubular Carcinoma and Invasive Lobular Carcinoma (2007) (255)
- The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer (2009) (254)
- Emerging therapeutic targets in endometrial cancer (2011) (254)
- Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. (2012) (252)
- Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. (2004) (250)
- Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. (2014) (243)
- PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors (2010) (243)
- Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. (2018) (239)
- Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer (2007) (238)
- Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray (2003) (232)
- Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (2014) (229)
- Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis (2007) (227)
- Morphologic and Molecular Evolutionary Pathways of Low Nuclear Grade Invasive Breast Cancers and Their Putative Precursor Lesions: Further Evidence to Support the Concept of Low Nuclear Grade Breast Neoplasia Family (2008) (226)
- The molecular underpinning of lobular histological growth pattern: a genome‐wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype‐matched invasive ductal carcinomas of no special type (2010) (225)
- Progression from ductal carcinoma in situ to invasive breast cancer: Revisited (2013) (220)
- Analysis of PALB2/FANCN-associated breast cancer families (2007) (219)
- Combinatorial biomarker expression in breast cancer (2010) (217)
- Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer (2012) (213)
- Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis (2009) (212)
- Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis (2009) (207)
- Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival (2016) (205)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment (2010) (196)
- Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue (2008) (190)
- Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas (2010) (183)
- Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity (2005) (181)
- Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers (2009) (181)
- Next-generation sequencing (2009) (180)
- Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands (2014) (178)
- PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS (2016) (174)
- An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers (2010) (173)
- The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. (2019) (172)
- Salivary gland-like tumours of the breast: surgical and molecular pathology (2003) (171)
- Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations (2011) (170)
- Circulating tumour cells and cell-free DNA as tools for managing breast cancer (2013) (168)
- Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis (2005) (168)
- Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis (2006) (167)
- Patient-derived xenograft (PDX) models in basic and translational breast cancer research (2016) (166)
- FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo (2011) (164)
- Whole genome sequencing of matched primary and metastatic acral melanomas. (2012) (161)
- SF3B1 mutations constitute a novel therapeutic target in breast cancer (2014) (161)
- p63 expression in normal skin and usual cutaneous carcinomas (2002) (158)
- Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer (2017) (156)
- Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes (2017) (156)
- Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma (2007) (155)
- Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal selection (2012) (154)
- PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas (2009) (153)
- Functional viability profiles of breast cancer. (2011) (151)
- Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type. (2011) (151)
- CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome (2008) (150)
- Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. (2011) (148)
- Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes (2004) (148)
- Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype (2008) (145)
- Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines (2008) (144)
- Tackling the Diversity of Triple-Negative Breast Cancer (2013) (143)
- Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type (2010) (143)
- Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. (2015) (142)
- The diagnosis and management of pre-invasive breast disease: Genetic alterations in pre-invasive lesions (2003) (141)
- Are triple-negative tumours and basal-like breast cancer synonymous? (2007) (140)
- A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations (2014) (139)
- In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2+ breast cancer (2015) (138)
- Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers (2012) (137)
- Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data (2006) (136)
- Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer (2016) (136)
- Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement (2011) (136)
- Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction (2011) (135)
- The impact of expression profiling on prognostic and predictive testing in breast cancer (2006) (135)
- Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. (2015) (135)
- Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas (2009) (132)
- The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. (2005) (131)
- Novel and Classic Myoepithelial/Stem Cell Markers in Metaplastic Carcinomas of the Breast (2003) (130)
- The diagnosis and management of pre-invasive breast disease: Pathology of atypical lobular hyperplasia and lobular carcinoma in situ (2003) (130)
- A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer. (2007) (128)
- Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas) (2010) (128)
- Genomic landscape of adenoid cystic carcinoma of the breast (2015) (128)
- Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets (2009) (125)
- Epithelial and Mesenchymal Subpopulations Within Normal Basal Breast Cell Lines Exhibit Distinct Stem Cell/Progenitor Properties (2012) (125)
- Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations (2014) (123)
- Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas (2011) (123)
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. (2019) (123)
- Challenges translating breast cancer gene signatures into the clinic (2012) (122)
- Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer (2009) (121)
- PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines (2013) (119)
- An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer (2017) (118)
- Taking Advantage of Basic Research: p63 Is a Reliable Myoepithelial and Stem Cell Marker (2002) (118)
- The Genomic Landscape of Male Breast Cancers (2016) (118)
- Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants (2016) (117)
- Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer (2012) (117)
- Clinical and Biological Significance of E-cadherin Protein Expression in Invasive Lobular Carcinoma of the Breast (2010) (117)
- Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry (2013) (117)
- Tumor size and survival in breast cancer—a reappraisal (2010) (117)
- Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis (2007) (116)
- Polymorphous low‐grade adenocarcinoma of the salivary glands with transformation to high‐grade carcinoma (2002) (114)
- Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer (2007) (114)
- β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast (2010) (112)
- p63 Expression in Solid Cell Nests of the Thyroid: Further Evidence for a Stem Cell Origin (2003) (110)
- Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification (2015) (110)
- The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas (2017) (109)
- Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. (2006) (108)
- Going with the Flow: From Circulating Tumor Cells to DNA (2013) (107)
- Biomarker studies: a call for a comprehensive biomarker study registry (2011) (107)
- Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type (2009) (106)
- The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. (2014) (106)
- Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples (2017) (103)
- Chromogenic and fluorescent in situ hybridization in breast cancer. (2007) (103)
- The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. (2017) (101)
- The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. (2018) (99)
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. (2019) (99)
- Identification of NTN4, TRA1, and STC2 as Prognostic Markers in Breast Cancer in a Screen for Signal Sequence Encoding Proteins (2007) (98)
- Is TTF1 a good immunohistochemical marker to distinguish primary from metastatic lung adenocarcinomas? (2000) (97)
- Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas (2018) (97)
- Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast (2014) (96)
- Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. (2019) (96)
- HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. (2020) (96)
- Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype (2007) (95)
- Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection (2020) (93)
- Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry (2010) (92)
- The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer (2015) (91)
- Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue (2006) (91)
- Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients (2021) (91)
- Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs (2020) (90)
- Basal-like breast carcinoma: from expression profiling to routine practice. (2009) (90)
- Salivary duct carcinomas can be classified into luminal androgen receptor‐positive, HER2 and basal‐like phenotypes * (2012) (90)
- Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression (2016) (90)
- Microarray-based Gene Expression Profiling as a Clinical Tool for Breast Cancer Management: Are We There Yet? (2009) (89)
- Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype? (2009) (89)
- Processed pseudogenes acquired somatically during cancer development (2014) (87)
- ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer (2020) (87)
- EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines (2009) (87)
- Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization (2006) (86)
- Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. (2011) (86)
- Molecular Profiling: Moving Away from Tumor Philately (2010) (86)
- Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. (2015) (86)
- Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers (2011) (86)
- HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. (2019) (83)
- DICER1 hotspot mutations in non-epithelial gonadal tumours (2013) (83)
- An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers (2016) (83)
- The molecular basis of breast cancer pathological phenotypes (2017) (82)
- Diverse alterations associated with resistance to KRAS(G12C) inhibition (2021) (82)
- IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. (2016) (81)
- Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors (2020) (81)
- Immunophenotypic and genomic characterization of papillary carcinomas of the breast (2012) (81)
- Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. (2010) (80)
- Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. (2013) (80)
- HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer (2017) (79)
- Uterine adenosarcomas are mesenchymal neoplasms (2016) (79)
- Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases (2017) (78)
- Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy (2020) (78)
- Patho-biological aspects of basal-like breast cancer (2009) (78)
- Genetic Alterations of Triple Negative Breast Cancer By Targeted Next Generation Sequencing And Correlation With Tumor Morphology (2016) (78)
- Distribution and significance of 14‐3‐3σ, a novel myoepithelial marker, in normal, benign, and malignant breast tissue (2004) (78)
- Aurora-A Regulation of Nuclear Factor-κB Signaling by Phosphorylation of IκBα (2007) (77)
- Expression of c-met Tyrosine Kinase Receptor Is Biologically and Prognostically Relevant for Primary Cutaneous Malignant Melanomas (2003) (76)
- Molecular characterisation of cell line models for triple-negative breast cancers (2012) (76)
- MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast (2015) (76)
- Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis (2008) (75)
- Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein (2016) (75)
- The role of molecular analysis in breast cancer (2009) (75)
- The role of caveolin-1 in human breast cancer (2011) (75)
- Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018) (75)
- A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines (2009) (75)
- Mixed micropapillary–ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components (2009) (75)
- Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy (2011) (75)
- The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. (2007) (75)
- The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. (2018) (74)
- FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer (2019) (74)
- Getting it right: designing microarray (and not ‘microawry’) comparative genomic hybridization studies for cancer research (2007) (73)
- TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers (2016) (73)
- Molecular Classification of Estrogen Receptor-positive/Luminal Breast Cancers (2012) (72)
- Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity (2018) (72)
- Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival (2014) (71)
- A mouse model of melanoma driven by oncogenic KRAS. (2010) (71)
- A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks (2010) (70)
- Breast cancer intratumor genetic heterogeneity: causes and implications (2012) (70)
- Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy (2020) (70)
- APRIN is a cell cycle specific BRCA2‐interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer (2012) (70)
- Nestin is expressed in basal-like and triple negative breast cancers (2008) (70)
- The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers (2010) (69)
- Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival (2015) (69)
- Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma (2009) (68)
- Lymphangiogenesis in tumors: What do we know? (2003) (67)
- Metastasis and immune evasion from extracellular cGAMP hydrolysis. (2020) (67)
- Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer (2016) (66)
- Compromised BRCA1-PALB2 interaction is associated with breast cancer risk (2017) (66)
- MYC amplification in breast cancer: a chromogenic in situ hybridisation study (2006) (66)
- Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. (2007) (65)
- PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study (2010) (65)
- Functional characterization of the 19q12 amplicon in grade III breast cancers (2012) (65)
- CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification (2010) (65)
- A whole‐genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor‐negative and ‐positive breast cancers (2012) (65)
- Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib (2012) (65)
- Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation (2007) (64)
- Metaplastic breast carcinoma: more than a special type (2014) (64)
- Hereditary breast cancer: from molecular pathology to tailored therapies (2008) (63)
- the 11q13‐q14 amplicon: Clinicopathological correlations and potential drivers (2013) (63)
- Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer (2018) (63)
- Maspin expression in myoepithelial tumors of the breast. (2001) (62)
- Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. (2019) (61)
- Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests (2004) (61)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
- The Genomic Landscape of Mucinous Breast Cancer. (2019) (60)
- Genomic profiling of histological special types of breast cancer (2013) (59)
- MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB–NFIB fusion gene (2018) (58)
- Delivering precision oncology to patients with cancer (2022) (57)
- Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (2014) (57)
- Distribution of p63, a novel myoepithelial marker, in fine‐needle aspiration biopsies of the breast (2003) (57)
- Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. (2021) (57)
- Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. (2019) (57)
- Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers (2013) (56)
- Are Triple-Negative and Basal-Like Breast Cancer Synonymous? (2008) (56)
- Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy (2018) (55)
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. (2022) (55)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
- Dysregulated TRK Signalling is a Therapeutic Target in CYLD Defective Tumours (2011) (53)
- 14-3-3σ stabilizes a complex of soluble actin and intermediate filament to enable breast tumor invasion (2013) (53)
- Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy (2006) (52)
- The genetic landscape of breast carcinomas with neuroendocrine differentiation (2017) (52)
- Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse. (2006) (52)
- ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. (2021) (51)
- Transcriptome analysis of embryonic mammary cells reveals insights into mammary lineage establishment (2011) (51)
- Targeting chromosomal instability and tumour heterogeneity in HER2‐positive breast cancer (2010) (51)
- Non-operative breast pathology: columnar cell lesions (2006) (51)
- Amplification and Overexpression of CACNA1E Correlates with Relapse in Favorable Histology Wilms' Tumors (2006) (51)
- Next-generation sequencing applied to molecular diagnostics (2011) (51)
- Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast (2017) (50)
- Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast (2010) (50)
- Somatic complex I disruptive mitochondrial DNA mutations are modifiers of tumorigenesis that correlate with low genomic instability in pituitary adenomas. (2013) (50)
- The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis‐generating study (2015) (49)
- De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. (2017) (49)
- Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. (2018) (48)
- Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma (2009) (48)
- Maspin expression in normal skin and usual cutaneous carcinomas (2002) (48)
- Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (2018) (47)
- Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer? (2002) (47)
- Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. (2019) (47)
- Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis (2012) (46)
- Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers (2014) (46)
- Genetic Analysis of Microglandular Adenosis and Acinic Cell Carcinomas of the Breast Provides Evidence for the Existence of a Low-grade Triple-Negative Breast Neoplasia Family (2016) (46)
- Congenital composite hemangioendothelioma: case report and reappraisal of the hemangioendothelioma spectrum (2002) (46)
- Genomic profile of a secretory breast cancer with an ETV6–NTRK3 duplication (2009) (46)
- Metastatic breast carcinomas display genomic and transcriptomic heterogeneity (2015) (45)
- Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models (2014) (45)
- Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation (2009) (45)
- PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ—Implications for Progression to Invasive Breast Carcinoma (2014) (44)
- Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer (2010) (44)
- Intradermal spindle cell/pleomorphic lipoma of the vulva: case report and review of the literature (2002) (44)
- Genetic characterization of breast cancer and implications for clinical management (2009) (43)
- Genomic characterisation of acral melanoma cell lines (2012) (43)
- Microglandular adenosis associated with triple‐negative breast cancer is a neoplastic lesion of triple‐negative phenotype harbouring TP53 somatic mutations (2016) (43)
- Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast (2014) (43)
- Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways (2017) (43)
- Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort (2018) (42)
- Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. (2013) (42)
- Bi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer (2017) (42)
- Invasive Breast Carcinoma: Introduction and general features (2012) (42)
- Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box (2011) (42)
- Impact of Basal-Like Breast Carcinoma Determination for a More Specific Therapy (2008) (42)
- p63 staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast (2002) (41)
- Triple-negative breast cancers — a panoply of cancer types (2018) (41)
- Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. (2012) (41)
- Differential Prox-1 and CD 31 expression in mucousae, cutaneous and soft tissue vascular lesions and tumors. (2005) (41)
- Sex differences in oncogenic mutational processes (2019) (41)
- Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing (2014) (39)
- Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines (2011) (39)
- Molecular Alterations of KIT Oncogene in Gliomas (2007) (39)
- Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships (2016) (38)
- Multifaceted Dysregulation of the Epidermal Growth Factor Receptor Pathway in Clear Cell Sarcoma of the Kidney (2007) (37)
- Taxane benefit in breast cancer—a role for grade and chromosomal stability (2013) (37)
- AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients (2016) (37)
- Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. (2014) (37)
- Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential (2019) (37)
- Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype‐matched ductal and lobular carcinomas (2010) (37)
- Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas (2008) (37)
- Synthetic Lethality in Cancer Therapeutics: The Next Generation. (2021) (37)
- Translating neoadjuvant therapy into survival benefits: one size does not fit all (2016) (37)
- Genome‐wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c‐Kit, CD117) and oestrogen receptor‐α (ERα) in response to therapeutic radiation (2009) (37)
- Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor‐positive, invasive breast cancer (2011) (36)
- Genomic profile of advanced breast cancer in circulating tumour DNA (2021) (36)
- Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations (2013) (35)
- Non-operative breast pathology: lobular neoplasia (2006) (35)
- Functional characterization of EMSY gene amplification in human cancers (2011) (35)
- Composite cervical adenocarcinoma composed of adenoma malignum and gastric type adenocarcinoma (dedifferentiated adenoma malignum) in a patient with Peutz Jeghers syndrome (2010) (35)
- Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome (2014) (35)
- Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma (2018) (34)
- Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (34)
- Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. (2016) (34)
- Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management (2016) (34)
- Mammary Epithelioid Myofibroblastoma Arising in Bilateral Gynecomastia (2001) (34)
- P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. (2002) (33)
- A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. (2019) (33)
- Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer (2019) (33)
- Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative (2021) (33)
- Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study (2010) (32)
- Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases (2021) (32)
- Evaluation of cell proliferation, epidermal growth factor receptor, and bcl‐2 immunoexpression as prognostic factors for patients with world health organization grade 2 oligodendroglioma (2000) (32)
- Primary epithelial malignant mesothelioma of the pericardium with deciduoid features: Cytohistologic and immunohistochemical study (2002) (32)
- Lobular in situ neoplasia and columnar cell lesions: diagnosis in breast core biopsies and implications for management (2007) (32)
- Phenotype-Genotype Correlation in Familial Breast Cancer (2011) (32)
- Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases (2018) (32)
- Contralateral breast cancers: Independent cancers or metastases? (2018) (32)
- Clinicopathologic implications of E‐cadherin reactivity in patients with lobular carcinoma in situ of the breast (2002) (31)
- Eosinophilic angiocentric fibrosis of the sinonasal tract: Report on the clinicopathologic features of a case and review of the literature (2002) (31)
- Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion (2015) (31)
- FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. (2020) (30)
- Cytokeratin 5/6 in normal human breast: lack of evidence for a stem cell phenotype (2004) (30)
- Oncocytic change in pleomorphic adenoma: molecular evidence in support of an origin in neoplastic cells (2006) (30)
- Independent real‐world application of a clinical‐grade automated prostate cancer detection system (2021) (30)
- Are acinic cell carcinomas of the breast and salivary glands distinct diseases? (2015) (30)
- Metastatic breast carcinomas display genomic and transcriptomic heterogeneity (2015) (30)
- Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer (2022) (29)
- Hypoxia can be detected in irradiated normal human tissue: a study using the hypoxic marker pimonidazole hydrochloride. (2007) (29)
- Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer (2010) (29)
- c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours (2007) (29)
- DICER1 hotspot mutations in non-epithelial gonadal tumours (2013) (29)
- Activating mutations in HER2: neu opportunities and neu challenges. (2013) (28)
- Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies (2014) (28)
- Pathogenesis of Triple-Negative Breast Cancer. (2022) (28)
- Beyond triple-negative breast cancer: the need to define new subtypes (2010) (28)
- Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor (2016) (27)
- Perilobar Nephrogenic Rests Are Nonobligate Molecular Genetic Precursor Lesions of Insulin-Like Growth Factor-II-Associated Wilms Tumors (2008) (27)
- Implications of rarity of chromosome 17 polysomy in breast cancer. (2011) (27)
- Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. (2020) (27)
- Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary (2020) (27)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (27)
- The molecular genetic make-up of male breast cancer. (2019) (27)
- The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. (2019) (27)
- Direct evidence for concurrent morphological and genetic heterogeneity in an invasive ductal carcinoma of triple-negative phenotype (2011) (26)
- Oncocytic carcinoma of the breast: frequency, morphology and follow-up. (2011) (26)
- Sarcomatoid variant of anaplastic large cell lymphoma mimicking a primary breast cancer: a challenging diagnosis. (2002) (26)
- Primary fibromatosis of the breast in a patient with multiple desmoid tumors--report of a case with evaluation of estrogen and progesterone receptors. (2001) (26)
- Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy (2019) (25)
- Classic Kaposi's sarcoma of the tongue: case report with emphasis on the differential diagnosis. (2002) (25)
- Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure (2015) (25)
- A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF. (2010) (24)
- Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (24)
- INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors (2021) (24)
- Epistatic interactions and drug response (2014) (24)
- Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma (2020) (24)
- Somatic mutations in leukocytes infiltrating primary breast cancers (2015) (23)
- Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations. (2012) (23)
- Lack of PRKD2 and PRKD3 kinase domain somatic mutations in PRKD1 wild‐type classic polymorphous low‐grade adenocarcinomas of the salivary gland (2016) (23)
- BRCA1 and stem cells: tumour typecasting (2008) (23)
- Where Birt–Hogg–Dubé meets Cowden Syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours (2013) (23)
- Generation of conditional oncogenic chromosomal translocations using CRISPR–Cas9 genomic editing and homology‐directed repair (2017) (23)
- Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile (2016) (23)
- DNA amplifications in breast cancer: genotypic-phenotypic correlations. (2010) (22)
- P63-driven nuclear accumulation of beta-catenin is not a frequent event in human neoplasms. (2003) (22)
- ESR1 gene amplification in breast cancer: a common phenomenon? (2008) (22)
- Cell-free DNA (cfDNA) mutations from clonal hematopoiesis: Implications for interpretation of liquid biopsy tests. (2017) (22)
- Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary (2020) (22)
- Immunohistochemical Analysis of IDH2 R172 Hotspot Mutations in Breast Papillary Neoplasms: Applications in the Diagnosis of Tall Cell Carcinoma with Reverse Polarity (2019) (22)
- Naked nuclei revisited: p63 Immunoexpression (2002) (22)
- Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing (2016) (22)
- Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers (2019) (22)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Maspin is expressed in the nuclei of breast myoepithelial cells (2002) (21)
- Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. (2019) (21)
- Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG) (2020) (21)
- High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform (2011) (21)
- Vascular endothelial growth factor, transforming growth factor-alpha, and estrogen receptors: possible cross-talks and interactions. (2002) (21)
- Non-existence of caveolin-1 gene mutations in human breast cancer (2011) (20)
- Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis‐generating study (2017) (20)
- Pediatric pigmented dermatofibrosarcoma protuberans (Bednár tumor): case report and review of the literature with emphasis on the differential diagnosis. (2002) (20)
- HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway (2021) (20)
- Angiogenesis in lymph node metastases (2002) (20)
- Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas (2019) (20)
- August 2003: 47‐year‐old female with a 7‐year history of osteomalacia and hypophosphatemia (2004) (20)
- DNA Copy Number Aberrations, and Human Papillomavirus Status in Penile Carcinoma. Clinico-Pathological Correlations and Potential Driver Genes (2016) (20)
- V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer. (2019) (20)
- Amphicrine gastric carcinoma. (2001) (20)
- Absence of microsatellite instability in mucinous carcinomas of the breast. (2010) (20)
- PAX8–GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid (2019) (20)
- Problematic breast tumors reassessed in light of novel molecular data (2020) (19)
- A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability. (2020) (19)
- Determining PD-L1 Status in Patients with Triple-Negative Breast Cancer: Lessons Learned from IMpassion130. (2021) (19)
- Lobular in situ neoplasia (2004) (19)
- Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma (2020) (19)
- Bilateral gonadoblastomas in a dog with mixed gonadal dysgenesis. (2004) (19)
- Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma (2021) (19)
- Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer (2008) (19)
- Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer (2017) (19)
- Fluorescence in situ hybridization, comparative genomic hybridization, and other molecular biology techniques in the analysis of effusions (2005) (18)
- Molecular diagnosis in breast cancer (2008) (18)
- Differential Ki67 and bcl‐2 immunoexpression in solid–glandular and spindle cell components of biphasic synovial sarcoma: a double immunostaining assessment with cytokeratin and vimentin (2002) (18)
- Comparative Genomic Hybridisation Arrays: High-Throughput Tools to Determine Targeted Therapy in Breast Cancer (2008) (18)
- Collagenous spherulosis in an adenomyoepithelioma of the breast (2003) (18)
- Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology (2012) (18)
- Microglandular adenosis: a non-obligate precursor of triple-negative breast cancer? (2013) (18)
- Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. (2015) (18)
- Histologic Spectrum of Polymorphous Adenocarcinoma of the Salivary Gland Harbor Genetic Alterations Affecting PRKD Genes (2019) (18)
- Invasion in breast lesions: the role of the epithelial–stroma barrier (2018) (18)
- Genome-wide expression profiling as a clinical tool (2009) (18)
- Ultraviolet radiation drives mutations in a subset of mucosal melanomas (2021) (17)
- An introduction to genes, genomes and disease (2010) (17)
- Breast pathology: beyond morphology. (2010) (17)
- BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. (2020) (17)
- Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping (2012) (16)
- The genomic landscape of metastatic histologic special types of invasive breast cancer (2020) (16)
- Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas (2019) (16)
- Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma (2019) (15)
- Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance. (2014) (15)
- PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. (2015) (15)
- Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer (2021) (15)
- Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. (2019) (15)
- Recurrent MED12 exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults (2018) (15)
- Low-estrogen receptor-positive breast cancer: the impact of tissue sampling, choice of antibody, and molecular subtyping. (2012) (15)
- Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance (2014) (15)
- The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas (2020) (15)
- Abstract 5277: The cBioPortal for cancer genomics and its application in precision oncology (2016) (14)
- Glassy Cell Carcinoma of the Uterine Cervix (2001) (14)
- Pseudoepitheliomatous hyperplasia in cutaneous malignant melanoma: a rare and misleading feature. (2001) (14)
- The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers (2019) (14)
- Novel patterns of complex structural variation revealed across thousands of cancer genome graphs (2019) (14)
- Whole‐exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast (2019) (14)
- Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors. (2019) (14)
- Mutant SF3B1 promotes AKT and NF-kB driven mammary tumorigenesis. (2020) (13)
- Diverse BRCA 1 and BRCA 2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer (2017) (13)
- Epithelioid malignant peripheral nerve sheath tumour: case report and review of the previously published cases (2002) (13)
- Caveolin-1 P132L mutation in human cancers: 1 CAVeat to be voiced. (2010) (13)
- Enhanced RAD21 Cohesin Expression Confers Poor Prognosis and Resistance to Chemotherapy in High Grade Luminal, Basal, and HER 2 Breast Cancers (2014) (13)
- Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway (2019) (13)
- P‐cadherin expression in canine lactating mammary gland (2002) (13)
- Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. (2021) (12)
- April 2001: a 70 year old woman with recurrent meningioma. (2001) (12)
- The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features (2021) (12)
- Malignant peripheral nerve sheath tumour-like primary cutaneous malignant melanoma (2004) (12)
- Pathology in drug discovery and development (2014) (12)
- Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer (2016) (12)
- Identification of NTN 4 , TRA 1 , and STC 2 as Prognostic Markers in Breast Cancer ina Screenfor Signal Sequence EncodingProteins (2007) (12)
- Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications (2017) (11)
- Cavernous sinus thrombosis caused by zygomycosis after unrelated bone marrow transplantation (2001) (11)
- Pathologic quiz case: a 62-year-old woman with a 4.5-cm nodule in the right breast. Lipid-rich breast carcinoma. (2003) (11)
- Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes (2020) (11)
- Pathologic Quiz Case: A 93-Year-Old Woman With an Enlarged and Tender Left Breast (2003) (11)
- Development of therapeutic approaches to 'triple negative' phenotype breast cancer. (2008) (10)
- Massively parallel sequencing analysis of benign melanocytic naevi (2019) (10)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
- Pathologic Quiz Case: A 36-Year-Old Woman With Muscle Pain and Weakness (2002) (10)
- Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes (2020) (10)
- CAV1 and CAV2 are associated with breast cancer basal-like and triple negative immunophenotype (2008) (10)
- Hyaline cell-rich chondroid syringoma: case report and review of the literature. (2002) (10)
- Primary cutaneous malignant melanoma with lipoblast-like cells. (2003) (9)
- Pathologic quiz case. A 36-year-old woman with muscle pain and weakness. Phosphaturic mesenchymal tumor (mixed connective tissue variant)/oncogenic osteomalacia. (2002) (9)
- Cancer Causative Mutations Occurring in Early Embryogenesis. (2021) (9)
- High-resolution genomic profiling of thyroid lesions uncovers preferential copy number gains affecting mitochondrial biogenesis loci in the oncocytic variants. (2015) (9)
- Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors (2021) (9)
- Molecular Classification of Breast Cancer. (2012) (9)
- Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management (2020) (9)
- Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging. (2021) (9)
- Re: Korsching et al. The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005; 206: 451–457 (2005) (9)
- Tumor and Stem Cell Biology Cancer Research FGFR 1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer (2010) (9)
- Transcriptional upregulation and unmethylation of the promoter region of p16 in invasive basal cell carcinoma cells and partial co‐localization with the γ2 chain of laminin‐332 (2007) (9)
- Giant cell collagenoma: case report and review of the literature (2002) (8)
- Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer. (2017) (8)
- Single-cell genomic variation induced by mutational processes in cancer (2022) (8)
- CASES OF THE MONTH: April 2001 – June 2001 (2001) (8)
- Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer (2015) (8)
- Oncogenic properties and signaling basis of the PAX8‐GLIS3 fusion gene (2020) (8)
- Expression of Hepatocyte Growth Factor and Its Receptor Met in Wilms' Tumors and Nephrogenic Rests Reflects Their Roles in Kidney Development (2009) (8)
- Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours (2007) (8)
- Evaluating clonal hematopoiesis in tumor infiltrating leukocytes in breast cancer and secondary hematologic malignancies. (2019) (8)
- Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast (2017) (8)
- c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant? (2003) (7)
- Abstract 8: Genomic analyses of heterogeneous HER2 3+ invasive ductal carcinomas of the breast (2012) (7)
- Homologous recombination deficiency: how genomic signatures are generated. (2021) (7)
- SCLEROSING EPITHELIOID MESENCHYMAL NEOPLASM OF THE PANCREAS A PROPOSED NEW ENTITY (2019) (7)
- The Birth of an Adenoid Cystic Carcinoma (2015) (7)
- Oncogenes, granules and breast cancer: what has c-myc to do with apocrine changes? (2002) (7)
- RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. (2016) (7)
- The genomic landscape of carcinomas with mucinous differentiation (2021) (7)
- AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling (2020) (7)
- Microarray‐Based Comparative Genomic Hybridization (2009) (7)
- Genomic characterization of small cell carcinomas of the uterine cervix (2021) (7)
- Pathologic quiz case: a 93-year-old woman with an enlarged and tender left breast. Histiocytoid variant of lobular breast carcinoma. (2003) (6)
- TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer (2021) (6)
- Lobular Neoplasia and Invasive Lobular Carcinoma (2012) (6)
- Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. (2021) (6)
- Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development (2021) (6)
- (V600E)Braf::Tyr-CreERT2::K14-Kitl mice do not develop superficial spreading-like melanoma: keratinocyte Kit ligand is insufficient to "translocate" (V600E)Braf-driven melanoma to the epidermis. (2012) (6)
- Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes (2020) (6)
- Glassy cell carcinoma of the uterine cervix. Report of a case with cytohistologic and immunohistochemical study. (2001) (6)
- Genomic analysis of recurrences and high‐grade forms of polymorphous adenocarcinoma (2019) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
- ESR1 and endocrine therapy resistance: more than just mutations. (2018) (6)
- Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing (2022) (6)
- Abstract CT030: Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1/2 TRESR trial (2022) (5)
- The Molecular Evolution of Breast Cancer Precursors and Risk Indicators (2011) (5)
- Pathology and Molecular Pathology of Breast Cancer (2017) (5)
- The impact of mutational processes on structural genomic plasticity in cancer cells (2021) (5)
- Immunohistochemistry and Molecular Biology of Breast Cancers: Old and New Prognostic Factors (2011) (5)
- Ki67 Assessment in Breast Cancer: Are We There yet? (2020) (5)
- Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. (2014) (5)
- Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype? (2017) (5)
- Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype? (2017) (5)
- Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification (2015) (5)
- [Primary pediatric tumours of the central nervous system. Anatomopathological study of 623 cases]. (1997) (5)
- Whole‐exome analysis of metaplastic breast carcinomas with extensive osseous differentiation (2020) (5)
- APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. (2022) (5)
- Anti-HER2 therapies: when more is more (2012) (4)
- Rectal leiomyosarcoma mna dog and review of gastrointestinal stromal tumours (2003) (4)
- Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors (2021) (4)
- Prognostic signatures in breast cancer: correlation does not imply causation (2012) (4)
- Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies (2019) (4)
- Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome (2021) (4)
- Lipoma-like hibernoma: an atypical lipoma/well-differentiated liposarcoma mimicker (2002) (4)
- Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. (2021) (4)
- Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. (2022) (4)
- MSK-ACCESS for noninvasive somatic mutation profiling of lung cancers utilizing circulating tumor DNA. (2020) (4)
- Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. (2021) (4)
- Back to the basis: breast cancer heterogeneity from an etiological perspective. (2014) (4)
- Columnar cell lesions of the breast (2005) (4)
- From Expression Profiling to Routine Practice (2009) (4)
- Fine needle aspiration cytology of paratesticular rhabdomyosarcoma mimicking a testicular germ cell tumor. (2002) (4)
- Abstract GS2-01: High levels of interferon-response gene signatures are associated withde novoand acquired resistance to CDK4/6 inhibitors in ER+ breast cancer (2020) (4)
- Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). (2008) (4)
- Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies (2021) (4)
- Abstract GS4-08: Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance (2022) (4)
- [Genome-wide expression profiling as a clinical tool: are we there yet?]. (2009) (3)
- Pathologic quiz case: a 53-year-old man with a slowly enlarging mass in the right leg. (2009) (3)
- A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC). (2020) (3)
- Preclinical evaluation of PARP inhibition as a treatment for endometrioid endometrial carcinomas. (2010) (3)
- [Krabbe s disease - case report] (2000) (3)
- Abstract PD4-13: Estrogen receptor-negative breast adenomyoepitheliomas are driven by co-occurring HRAS hotspot and PI3K pathway gene mutations: A genetic and functional analysis (2018) (3)
- Abstract 927: Targeted capture next generation sequencing of fresh frozen lobular carcinoma in situ and invasive lobular cancer identifies a common repertoire of mutations (2014) (3)
- Integrative Molecular Profiling of Triple Negative Breast Cancers Identifies Potential Therapeutic Targets Including Amplifications of FGFR2. (2009) (3)
- Circulating Tumor DNA as a Biomarker in Oligometastatic Non-small Cell Lung Cancer (2020) (3)
- Ancillary Studies for Salivary Gland Cytology (2018) (3)
- Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer. (2009) (3)
- Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients (2022) (3)
- Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites (2020) (3)
- Pathogenic Mutations in ATM As Determinants of Local Control in Non-Small Cell Lung Cancers Treated with Radiation Therapy (2018) (3)
- Bcl2 as a surrogate prognostic and predictive marker in triple-negative breast cancer. (2011) (3)
- Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination (2021) (3)
- Lobular Carcinoma In Situ: Biology and Pathology (2004) (3)
- Abstract S4-03: A functional assay for homologous recombination (HR) DNA repair and whole exome sequencing reveal that HR-defective sporadic breast cancers are enriched for genetic alterations in DNA repair genes (2016) (3)
- Abstract PD6-5: Pooled analysis of circulating tumor cells in metastatic breast cancer: Findings from 1944 individual patients data (2013) (3)
- Reply to Rosen (2017) (2)
- Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma (2017) (2)
- Molecular genetics of ADH/DCIS and ALH/LCIS (2006) (2)
- Abstract 2547: Discovery and characterization of late-stage breast cancer estrogen receptor alpha 1 bound long non-coding RNAs (2017) (2)
- Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers. (2022) (2)
- MOLECULAR OF BREAST CANCER (2012) (2)
- Abstract 2138: Functional characterization of the 19q12 amplicon in grade 3 breast cancers (2010) (2)
- Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma (2021) (2)
- Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast (2020) (2)
- Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study (2021) (2)
- PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays (2021) (2)
- Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer. (2022) (2)
- Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes (2021) (2)
- PG 2.03 Discrepancies between genetic tools and immunohistochemistry: bad pathology and good signature, and vice-versa (2015) (2)
- Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers (2013) (2)
- Abstract S6-06: High-depth massively parallel sequencing reveals heterogeneity between primary tumor and metastatic deposits in de novo metastatic breast cancer patients prior to exposure to systemic therapy (2013) (2)
- Pathogenic Mutations in ATM Predict for Enhanced Local Control in Prostate Cancers Treated with Radiation Thearpy (2018) (2)
- Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression (2022) (2)
- Independent validation of paige prostate: Assessing clinical benefit of an artificial intelligence tool within a digital diagnostic pathology laboratory workflow. (2020) (2)
- Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer (2022) (2)
- Cancer Therapy : Preclinical PI 3 K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines (2013) (2)
- Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers (2022) (2)
- Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer. (2010) (2)
- 210O Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC) (2022) (2)
- Abstract S6-06: The genomic landscape of male breast cancers (2015) (2)
- Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations (2023) (2)
- Markers for Breast Cancer Myoepithelial Breast Cells : Identification of Novel Prognostic Expression Profiling of Purified Normal Human Luminal and Updated (2004) (2)
- Genomic determinants of early recurrences in low-stage low-grade endometrioid endometrial carcinoma. (2022) (1)
- Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116). (2022) (1)
- O-80 CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome (2007) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Pleomorphic lobular carcinoma in situ (2013) (1)
- Functional characterization of the 19q12 amplicon in grade III breast cancers (2012) (1)
- Abstract PD3-4: Reliability of whole exome sequencing for assessing intratumor heterogeneity from breast tumor biopsies (2015) (1)
- Abstract S4-02: Integrated genomic analyses of members of protein kinase C family identifies subtype specific alterations as novel therapeutic targets (2013) (1)
- Pathogenic Mutations in ATM Enhance Radio-Sensitivity and Local Control in Patients with Primary and Metastatic Breast Cancer (2018) (1)
- Triple negative and basal-like breast cancer : one or many diseases ? Implications for surgical pathologists (2009) (1)
- Letter Are triple-negative tumours and basal-like breast cancer (2007) (1)
- Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines (2009) (1)
- Human Cancer Biology PI 3 K Pathway Activation in High-Grade Ductal Carcinoma In Situ — Implications for Progression to Invasive Breast Carcinoma (2014) (1)
- Abstract 949: ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer (2019) (1)
- Homologous recombination DNA repair defects in copy-number high serous-like endometrial cancers (2019) (1)
- Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations (2014) (1)
- Abstract A2-02: SF3B1 mutations constitute a novel therapeutic target in breast cancer (2015) (1)
- Reactive spindle cell nodules of the breast. (2001) (1)
- Bcl2 expression and prediction of outcomes to anthracycline-based neoadjuvant chemotherapy in ER-positive breast cancer and to nonanthracycline adjuvant therapy. (2011) (1)
- Breast cancer intra-tumor heterogeneity (2014) (1)
- Ewing's sarcoma of the rectum: can we afford not to use molecular pathology? (2005) (1)
- Blastemal/stromal expression of IGF1R in Wilms tumours is driven by increased copy number and correlates with relapse (2006) (1)
- Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (1)
- Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast (2017) (1)
- Whole‐exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma (2020) (1)
- Triple-Negative and Basal-like Carcinoma (2012) (1)
- A Randomised Multicentre Trial of Epirubicin, Oxaliplatin and Capecitabine (EOC) + Panitumumab in advanced Oesophago-Gastric Cancer (REAL3): Updated Results (2012) (1)
- Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (1)
- Lobular Carcinoma In Situ : Biology and Management (2013) (1)
- Combining two antibodies to define E‐cadherin loss of expression in non‐lobular breast carcinomas: when less is more (2013) (1)
- High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants (2019) (1)
- The importance of gene-centring microarray data – Authors' reply (2010) (1)
- Patient-derived xenograft (PDX) models in basic and translational breast cancer research (2016) (1)
- An Investigation into a Panel of Isogenic Taxane Resistant Breast Cancer Cell Lines Using Transcriptomic and Genomic Methods. (2009) (1)
- Abstract P2-13-19: Statin modulation of antibody drug conjugate activity in breast cancer models and patients (2022) (1)
- Preclinical evaluation of the PARP-inhibitor olaparib for the treatment of ovarian clear cell cancer (2011) (1)
- Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance (2014) (1)
- Abstract P3-06-08: Mucinous and neuroendocrine breast cancers: A spectrum of genetically-related lesions distinct from common forms of estrogen receptor-positive breast cancers (2019) (1)
- Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix (2022) (1)
- Molecular diagnostics: the key driver in personalized cancer medicine, Jan T Jorgensen, Henrik Winther (Eds.). Pan Stanford Publishing (2010), Pp 300, £121.95., ISBN: 978-9814241441 (2010) (1)
- Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications (2022) (1)
- LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer (2022) (1)
- Abstract S2-02: The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers (2016) (1)
- Cutaneous Malignant Melanoma: The Great Simulator (2003) (1)
- Invasive micropapillary breast cancer: Single-institution experience in the modern era. (2013) (1)
- Abstract P1-07-06: Immune signatures define and affect prognosis in triple-negative breast cancer subtypes (2017) (1)
- Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. (2020) (1)
- An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers (2016) (1)
- Abstract 4167: Ultraviolet radiation cooperates with individual oncogenes to drive melanomagenesis through distinct molecular mechanisms (2016) (1)
- Rare Breast Carcinomas (2012) (1)
- Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers (2022) (1)
- Pathologic quiz case. Multicystic ovarian tumor in a 46-year-old female patient. (2009) (1)
- Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers (2022) (1)
- Predictive Biomarkers and Personalized Medicine A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer (2010) (1)
- Abstract 1787: Statin therapy enhances the efficacy of HER2 directed antibody-drug conjugates in breast cancer (2022) (1)
- Prognostic signatures in breast cancer: correlation does not imply causation (2012) (1)
- A New Pathological Response Index (PRI) for Neoadjuvant Chemotherapy Accurately Predicts Clinical Outcomes of Locally Advanced Primary Breast Cancers (LAPBC) (2011) (1)
- Early ctDNA response assessment for prediction of platinum sensitivity in small cell lung cancer. (2020) (1)
- Abstract P4-05-08: Genomic landscape of breast cancer occurring in elderly individuals (2020) (1)
- Abstract 2989: Intra-tumor heterogeneity and clonal changes in the progression of DCIS to invasiveness: Combined tumor bulk and single cell analysis (2015) (1)
- Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy (2022) (1)
- Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma (2021) (1)
- 99P Analysis of ctDNA in advanced breast cancer reveals polyclonal disease associated with adverse outcome (2021) (1)
- Topoisomerase 2 alpha as a predictor of response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer (2010) (1)
- 5015 The need for a biological grading system and its relationship to the current Nottingham histological grading system (NGS) (2009) (1)
- Granular cell tumor of thyroid: a case series with molecular characterization highlighting unique pitfalls (2022) (1)
- ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance (2021) (1)
- Abstract PD05-08: Genomic characterisation of invasive breast cancers with heterogeneous HER2 gene amplification (2012) (1)
- Genomic Applications in Breast Carcinoma (2018) (1)
- Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles. (2022) (1)
- A 62-year-old woman with a 4.5-cm nodule in the right breast (2003) (1)
- Hemangioendothelioma Identification of a Disease-Defining Gene Fusion in Epithelioid (2011) (1)
- Pilot trial of an implantable microdevice for In Vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy. (2016) (1)
- Clinical Validation of Artificial Intelligence-Augmented Pathology Diagnosis Demonstrates Significant Gains in Diagnostic Accuracy in Prostate Cancer Detection. (2022) (1)
- [Neurocutaneous melanosis] (1999) (1)
- TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer (2021) (1)
- Abstract P6-03-10: Genomic and transcriptomic heterogeneity in metaplastic breast carcinomas (2016) (1)
- ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance (2022) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- Abstract 930: Analysis of cell-free tumor DNA in cerebrospinal fluid to characterize and monitor the genetic alterations of brain tumors (2015) (1)
- Abstract P4-02-03: Gene Copy Number Alterations Related to mRNA and miRNA Expression in Endocrine Resistant Breast Cancers (2010) (0)
- Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (0)
- Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA (2021) (0)
- Breast cancer phenotype and genetic alterations: how are they connected? (2008) (0)
- Abstract P4-02-01: High-depth sequencing of circulating tumor DNA to interrogate the genetics of residual micro-metastatic disease prior to relapse in early breast cancer (2015) (0)
- LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer (2022) (0)
- A novel tumour-based test to identify breast cancer due to BRCA1 and BRCA2 mutations (2010) (0)
- The molecular pathology of ER, PR HER2 negative breast cancers: finding novel biomarkers (2008) (0)
- P PROGNOSIS IMPACT OF POSTOPERATIVE RADIATION IN PATIENTS WITH RADICAL ESOPHAGECTOMY AND PATHOLOGIC LYMPH NODES POSITIVE ESOPHAGEAL CANCER (2012) (0)
- Abstract P4-02-18: Impact of clonal hematopoiesis on disease progression following CDK4/6 inhibitor therapy (2023) (0)
- Abstract P2-04-16: CD103+/PD-1+ T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition (2017) (0)
- Abstract 3376: Early onset of chromosomal instability in breast preneoplasia detected by single-cell genomics (2018) (0)
- [Cerebrovascular diseases in patients aged 15 to 40 years: neuropathological findings in 47 cases]. (2001) (0)
- Abstract P2-01-02: Whole exome sequencing analysis of the progression from ductal carcinomain situto invasive ductal carcinoma (2019) (0)
- Abstract 4509: Clinical genomic profiling of 1000 metastatic breast cancer patients: actionable targets, novel alterations, and clinical correlations (2016) (0)
- Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363). (2016) (0)
- Abstract 91: The mutational landscape of mucinous carcinomas of the breast (2016) (0)
- Abstract P2-06-04: Pathognomonic long molecule footprints of backup repair pathways in homologous recombination deficient cancers (2022) (0)
- Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas (2021) (0)
- Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer (2022) (0)
- Abstract P1-06-08: A p53-independent DNA damage response that regulates breast cancer phenotypes (2019) (0)
- Primary salivary clear cell tumors. (2003) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- 5175 Columnar cell lesions are the early precursors of some forms of invasive breast carcinoma – a new genetic map for the evolutionary pathway of low nuclear grade breast neoplasia (LNGBN) family (2009) (0)
- 229 Genetic heterogeneity of ovarian sex cord-stromal tumors (2019) (0)
- Issue Information (2018) (0)
- Abstract 1544: The clinical behavior of endometrioid and serous endometrial carcinomas is governed by distinct biological processes (2014) (0)
- Molecular alterations of PDGA and PDGFRA in Gliomas (2009) (0)
- Abstract 4829: Massively parallel RNA sequencing analysis of micropapillary carcinomas of the breast (2011) (0)
- Direct prediction of Homologous Recombination Deficiency from routine histology in ten different tumor types with attention-based Multiple Instance Learning: a development and validation study (2023) (0)
- Impact of clonal hematopoiesis on tumor control following radiation therapy. (2022) (0)
- Abstract 4284: Enhancing subclonal reconstruction algorithm for resolving complex tumor phylogenies from multi-sample tumor DNA sequencing (2023) (0)
- Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors (2021) (0)
- 86 Molecular Diagnostics in Breast Cancer – Getting Beyond ER, PR, HER2 and Proliferation (2012) (0)
- Abstract P4-05-07: Whole-exome and RNA-sequencing analyses of acinic cell carcinomas of the breast (2020) (0)
- Short communication Next-generation sequencing (0)
- Abstract P2-23-15: Histologic, immunohistochemical and genomic comparison between classic Invasive lobular carcinomas and lobular-like invasive ductal carcinomas (2023) (0)
- Abstract P3-04-07: Functional BRCA-pathway defects in sporadic breast cancers rarely show a significant reduction in BRCA-pathway proteins (2013) (0)
- Abstract 4835: Genetic determinants of mTOR inhibitor response in breast and endometrial cancer (2012) (0)
- P43: Genomic changes in favourable histology Wilms tumours analysed by genome-wide 1 Mb-spaced and chromosome 1 tiling-path array CGH (2005) (0)
- Abstract P4-05-01: Massively parallel sequencing analysis of microsatellite instability in breast cancer (2020) (0)
- Abstract 2132: Tumor heterogeneity of CCNE1 copy number assessed by fluorescence in situ hybridization (FISH) in ovarian and uterine cancers and correlation with cyclin E protein expression (2023) (0)
- Running title : CTCs and staging in MBC (2018) (0)
- Molecular investigation of breast cancer (2013) (0)
- 5174 POSTER Topoisomerase ∥α (TOPO2A) Protein Overexpression Predicts Response to Anthracycline-based Chemotherapy Irrespective of HER2 Status (2011) (0)
- Abstract P4-02-01: Efficacy of HER2 ADCs against HER2 inhibitor resistance alterations in the PI3K and MAPK pathways in HER2-positive breast cancer (2023) (0)
- Special Topics on Bioinformatics: Intro to Biomolecular Structures and Genetics (2010) (0)
- Abstract PD4-07: PD4-07 Uncovering molecular heterogeneity of mixed ductal and lobular carcinoma using digital spatial profiling (2023) (0)
- 575 SF3B1 mutations are associated with alternative splicing in ER-positive breast cancer (2014) (0)
- Male breast cancer : genomic profiling 1 The Genomic Landscape of Male Breast Cancers (2016) (0)
- Expression of HGF and it’s receptor MET in Wilms tumours and nephrohgenic rests (2007) (0)
- Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer (2020) (0)
- Detection of biallelic loss of DNA repair genes in formalin-fixed, paraffin-embedded tumor samples using a novel tumor-only sequencing panel. (2023) (0)
- Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas (2018) (0)
- Re: Sastre‐Garau et al. Inflammatory myofibroblastic tumour (inflammatory pseudotumour) of the breast: clinicopathological and genetic analysis of a case with evidence for clonality. J Pathol 2002; 196: 97–102 (2003) (0)
- Abstract P2-05-08: Mucinous breast carcinomas: A genomically distinct subtype of estrogen receptor-positive invasive breast cancers (2018) (0)
- 431 Distant metastatic spread and clonal evolution of high-grade endometrial cancers (2020) (0)
- Abstract PD1-06: Apobec mutagenesis is a pervasive feature of poor prognosis breast cancer associating with ESR1 wild type, endocrine resistant disease (2022) (0)
- Analysis of 134 formalin-fixed paraffin-em bedded synovial sarcomas by conventional RT-PCR, real time RT-PCR and dual colour FISH (2007) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Landscape of somatic genetic alterations in endometrioid endometrial cancers with germline and somatic PTEN mutations (2018) (0)
- The genomic profiling of penile carcinoma: DNA copy number aberrations and validation of candidate driver genes (2017) (0)
- Abstract P4-17-01: Genomic profiling of primary and metastatic breast cancer in men (2020) (0)
- Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development (2021) (0)
- Abstract P1-05-03: The genomic landscape of breast metaplastic carcinoma (2017) (0)
- Letter to the Editor (2008) (0)
- Abstract PD4-5: Longitudinal massively parallel sequencing analysis of circulating cell-free tumor DNA: A feasibility study (2013) (0)
- Identifying somatic oncogenic mutations in leukocytes that infiltrate primary breast cancers. (2015) (0)
- Abstract PD11-01: An artificial intelligence-based predictor of CDH1 biallelic mutations and invasive lobular carcinoma (2022) (0)
- Ultraviolet radiation drives mutations in a subset of mucosal melanomas (2021) (0)
- Molecular characterisation of cell line models for triple-negative breast cancers (2012) (0)
- Abstract P3-06-09: Test of association between Ki67 index of early breast cancer and local relapse after adjuvant hypofractionated radiotherapy. (2012) (0)
- Abstract P4-05-10: PIK3CA mutations are enriched in invasive lobular carcinomas and invasive mammary carcinomas with lobular features: Results from a TCGA sub-analysis (2013) (0)
- KIT genetic alterations in breast cancer (2022) (0)
- Abstract 5721: Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival (2023) (0)
- Abstract PD6-02: Digital MammaPrint and BluePrint using machine learning and whole slide imaging (2021) (0)
- Abstract P2-05-03: Novel driver genetic alterations in MYB-NFIB-negative breast adenoid cystic carcinomas (2018) (0)
- O-39 Morphological and molecular evolutionary pathways of low and high grade breast cancers and theier putative precursor lesions (2007) (0)
- Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients (2022) (0)
- How should we best target the biology of ER PR HER2 negative breast cancer (2008) (0)
- Abstract 6063: Genomic characterization of non-small cell lung cancer (NSCLC) brain metastasis (BM) patients identifies novel alterations associated with tropisms and disease progression (2023) (0)
- Abstract 138: Solid papillary carcinoma with reverse polarization are driven by IDH2 and PI3K pathway mutations (2016) (0)
- Hyperplastic/proliferating perilobar nephrogenic rests are molecular genetic precursor lesions of Wilms tumor (2007) (0)
- Mutation detection in cell-free DNA using ultra-high depth sequencing in prospectively collected newly diagnosed endometrial cancer patients (2020) (0)
- Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non–small cell lung cancer (NSCLC) treated with definitive radiation therapy. (2022) (0)
- Abstract PD14-03: Genetic and epigenetic basis of invasive lobular carcinomas lacking CDH1-alterations (2022) (0)
- Abstract PR05: The effect of chemotherapy on HER2+ breast cancer heterogeneity measured by STAR-FISH: Detection of PIK3CA mutation and HER2 amplification at single-cell level in situ (2016) (0)
- Abstract P6-05-10: An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas (2023) (0)
- Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers. (2022) (0)
- Abstract 709: The utility of plasma ctDNA for detection ofKRASG12C and other mutations in lung cancers (2020) (0)
- 902 ORAL Expression of KIT (c-Kit; CD117) is reduced after radiation in normal human breast tissue: a study using cDNA array analysis of microdissected samples (2007) (0)
- TERT Hotspot Promoter Mutations and TERT Gene Amplification in Phyllodes Tumors of the Breast (2016) (0)
- Abstract 3889: Genetic heterogeneity and distinct driver mutations in synchronous primary and metastatic breast cancers from therapy-naïve patients (2015) (0)
- Abstract P1-05-04: Intra-tumor genetic heterogeneity and histologic heterogeneity within metaplastic breast cancers: Genotypic-phenotypic correlations (2017) (0)
- Abstract A21: Modeling of oncogenic chromosomal translocations of aggressive fusion-positive sarcomas by CRISPR-Cas9 genomic engineering (2018) (0)
- CDK12 loss leads to replication stress and sensitivity to combinations of the ATR inhibitor camonsertib (RP-3500) with PARP inhibitors (2022) (0)
- Abstract 4472: PI3K pathway dependencies in endometrioid endometrial cancer. (2013) (0)
- Abstract P4-05-11: Methylation profiling of mucinous breast cancer (2020) (0)
- Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer (2015) (0)
- has shed light on the biological diversity of breast cancer by the identification of (2010) (0)
- Abstract 2801: Detection of biallelic loss of DNA repair genes in formalin-fixed, paraffin embedded (FFPE) tumor samples using a novel tumor-only sequencing panel with error correction (2022) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Abstract 4413: CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer (2019) (0)
- MicroArrays comparative genomic hybridisation (aCGH) and response to neoadjuvant chemotherapy (CT) in breast cancer (BC) (2005) (0)
- Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas (2019) (0)
- Abstract 1470: Ovarian cancer PDXs preserve preexisting genetic oligoclonality (2015) (0)
- Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer (2022) (0)
- Impact of mismatch repair (MMR) testing on colorectal cancer (CRC) oncology clinical practice. (2012) (0)
- Abstract 2470: Compromised BRCA1-PALB2 interaction is associated with breast cancer risk (2017) (0)
- 73 Proffered Paper: Glial Cell Line-derived Neurotrophic Factor (GDNF) Signaling as a Target for Endocrine Therapy Resistance in Breast Cancer (2012) (0)
- Abstract 1394: Comprehensive clinical and genomic analysis for patients with MYC, MYCN, and MYCL amplified solid tumors (2023) (0)
- Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer (2020) (0)
- Abstract P3-07-02: Metaplastic breast carcinomas and uterine carcinosarcomas are histologically and genetically related (2019) (0)
- Abstract 927: Genomic profiling of metastatic breast cancer identifies the Hippo pathway to be a key determinant of CDK4/6 inhibitor sensitivity (2019) (0)
- Abstract 3039: Identification of a novel biomarker of resistance to lapatinib common to both breast and oesophagogastric cancer (2011) (0)
- Abstract P2-03-08: Mutational landscape of metaplastic breast carcinomas (2015) (0)
- NR4A3 Expression is Consistently Absent in Acinic Cell Carcinomas of the Breast: A Potential Nosologic Shift. (2023) (0)
- Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models (2023) (0)
- Metaplastic Breast Cancer: Current Understanding and Future Directions (2023) (0)
- Abstract 5132: 14-3-3sigma coordinates breast tumor invasion by regulating cytoskeletal dynamics (2010) (0)
- Abstract P3-06-07: Recurrent but not pathognomonic fusion genes in mucinous carcinomas of the breast (2019) (0)
- Regression-based Deep-Learning predicts molecular biomarkers from pathology slides (2023) (0)
- Loss of the BRCA1-PALB2 interaction accelerates p53-associated tumor development in mice (2020) (0)
- Abstract 4735: Single-cell sequencing from formalin-fixed paraffin-embedded breast cancers: a powerful tool to address intratumor genetic heterogeneity (2015) (0)
- Gene-specific interactions between ultraviolet radiation and melanoma (2016) (0)
- Abstract P2-01-02: Capturing intra-tumor genetic heterogeneity in cell-free plasma DNA from patients with oligometastatic breast cancer (2016) (0)
- Endometrial cancers in or germline mutations carriers (2019) (0)
- Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge (2023) (0)
- Abstract 4817: Microsatellite instability status in endometrioid endometrial carcinomas is associated with distinct types and patterns of PI3K pathway mutations (2015) (0)
- Abstract 993: Identification of estrogen receptor alpha 1 bound lncRNAs in aggressive breast cancer (2016) (0)
- The Genomic Landscape of PALB2-Associated Breast Cancers (2017) (0)
- Abstract 2607: The cBioPortal for Cancer Genomics: an open source platform for accessing and interpreting complex cancer genomics data in the era of precision medicine (2017) (0)
- Abstract 2971: Whole exome sequencing reveals heterogeneity within lobular carcinoma in situ (LCIS) and clonal selection in the progression to malignant lesions (2015) (0)
- How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma (2019) (0)
- P1-06-22: Identification of Biomarkers in Breast Cancer for Prediction of Response to PARP Inhibitor Olaparib. (2011) (0)
- Abstract LB-335: Loss of function of the BRCA1-PALB2-BRCA2 axis accelerates p53-associated tumorigenesis (2020) (0)
- Histopathology would like to thank the following reviewers for their help in 2007: (2007) (0)
- Abstract P2-05-01: Single cell sequencing analysis of formalin-fixed paraffin-embedded ductal carcinomas in situ and invasive breast cancers reveals clonal selection in the progression from in situ to invasive disease (2016) (0)
- The genomic landscape of metastatic histologic special types of invasive breast cancer (2020) (0)
- Abstract 3917: EMSY amplification and overexpression is not associated with defective homologous recombination and does not predict sensitivity to cisplatin or PARP inhibitors (2011) (0)
- Abstract A184: Integrative molecular and functional profiling of HER2 amplified breast cancers to identify new gene targets. (2011) (0)
- Abstract A239: MPS1 (TTK) kinase inhibition selectively kills aneuploid cells (2009) (0)
- 234 Clonality analysis of synchronous endometrial and ovarian carcinomas in patients with lynch syndrome (2019) (0)
- Abstract 2949: Enabling single cell analysis of copy number variation in breast cancer (2022) (0)
- 12 Genetic analysis of primary and recurrent adult granulosa cell tumors of the ovary (2019) (0)
- Abstract C47: Inference of tumor evolution during chemotherapy by computational modeling and single cell analysis of diversity. (2013) (0)
- Abstract P2-03-09: Benchmarking mutation function prediction algorithms using validated cancer driver and passenger mutations (2015) (0)
- Abstract PD8-06: The genomic landscape of metastatic special histologic types of breast cancer (2020) (0)
- Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer (2012) (0)
- Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models (2022) (0)
- RESULTS Genomic Features of Advanced , Post-Treatment Breast Cancer (2019) (0)
- Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary (2020) (0)
- Abstract LB-031: Generation of inducible oncogenic chromosomal translocations using CRISPR-Cas9 genomic editing (2016) (0)
- Genetic alterations in pre-invasive lesions (2010) (0)
- Emerging therapeutic targets in endometrial (2011) (0)
- Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology (2023) (0)
- Abstract P4-04-08: Genomic and transcriptomic characterization of papillary carcinomas of the breast (2013) (0)
- Abstract PD8-09: Bi-allelic alterations in homologous recombination (HR) DNA repair-related genes as the basis for HR defects in human cancers: A pan-cancer genomics and functional analysis (2018) (0)
- situ hybridisation in breast carcinomas monoclonal antibody (SP3) and chromogenic in against Her2 including the novel rabbit Comparative analysis of six different antibodies (2009) (0)
- Abstract P6-13-02: The extent of lobular carcinoma in situ (LCIS) at surgical excision predicts for the development of subsequent breast cancer (2015) (0)
- Title: HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers Running title: Antitumoral activity of anti-HER2 ADCs in lung cancer (2020) (0)
- Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy (2022) (0)
- A Novel Tumour-Based Test To Identify Breast Cancer Due to BRCA1 and BRCA2 Mutations. (2009) (0)
- Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination (2021) (0)
- Use of topoisomerase II alpha (TOP2A) protein overexpression to predict response to anthracycline-based chemotherapy. (2011) (0)
- O18: Tiling path array CGH of breast cancer cell lines and integration with expression profiling (2005) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer (2020) (0)
- Abstract P2-09-03: Quantification of HER2 expression and spatial biology using computational pathology: A cross-assay validation study in breast cancer (2023) (0)
- The importance of gene-centring microarray data Reply (2010) (0)
- Abstract 6421: Molecular profiles and single cell analysis identify immunogenic pancreatic ductal adenocarcinoma (iPDAC) (2023) (0)
- Abstract 2488: Characterization of gene fusions in paired primary and metastatic samples of breast cancer in the AURORA molecular screening program (2020) (0)
- Abstract P4-05-15: Breast cancers with BRCA1 and BRCA2 mutations are associated with specific pathologic features and molecular profiles: Results from a TCGA sub-analysis (2013) (0)
- OP-ANNO190436 1417..1427 (2019) (0)
- Edinburgh Research Explorer Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer (2018) (0)
- Abstract HER2-07: HER2-07 Genomic Characterization of Primary and Metastatic HER2-low Breast Cancers (2023) (0)
- Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers (2022) (0)
- Abstract P2-03-01: Mutational landscape of breast cancers from PALB2 germline mutation carriers (2016) (0)
- Abstract 4029: The impact of multiple drug resistance mechanisms on microarray predictive gene signature performance. (2013) (0)
- Abstract PD11-02: Subtyping invasive carcinomas and high-risk lesions for machine learning based breast pathology (2022) (0)
- Abstract PD1-4: Somatic leukemogenic mutations associated with infiltrating white blood cells in breast cancer patients (2015) (0)
- Abstract S4-04: Lobular carcinoma in situ displays intra-lesion genetic heterogeneity and its progression to invasive disease involves clonal selection and variations in mutational processes (2016) (0)
- Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73]. (2021) (0)
- Abstract PD1-15: The landscape of somatic genetic alterations in breast cancers fromATMgermline mutation carriers (2018) (0)
- Abstract 4987: Identification of novel genes and pathways involved in resistance to HER2-targeting agents in breast cancer (2011) (0)
- Abstract 5688: RNA-mediated DNA repair: A novel repair pathway in homologous recombination-deficient cancers (2022) (0)
- Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies (2021) (0)
- Abstract 3379: Massively parallel sequencing analysis of breast adenomyoepitheliomas reveals the heterogeneity of the disease and identifies a subset driven byHRAShotspot mutations (2017) (0)
- Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes (2017) (0)
- Molecular subtypes and emerging therapeutic opportunities (2011) (0)
- Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways (2017) (0)
- Evaluating the association between clonal hematopoiesis and germline pathogenic and likely pathogenic variants in cancer predisposition genes. (2020) (0)
- Abstract GS3-03: Genomic analysis of 733 HER2+ breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities (2022) (0)
- Mapping the Molecular Alterations In IGF-Driven Wilms Tumorigenesis – Perilobar Nephrogenic Rests as Non-Obligate Molecular Genetic Precursor Lesions (2008) (0)
- O-21 Detection and quantification of microRNAs in laser microdissected formalin-fixed paraffin embedded (FFPE) breast cancer tissues (2010) (0)
- Abstract 5076: Integrative genomic and transcriptomic analysis of metaplastic carcinomas of the breast (2012) (0)
- ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications (2022) (0)
- Overcoming the challenges to implementation of artificial intelligence in pathology. (2023) (0)
- Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018) (0)
- High-sensitivity mutation analysis of cell-free DNA for disease monitoring in endometrial cancer. (2022) (0)
- Clinical Trials and Digital Pathology-Toward Quantitative Therapeutic Immunohistochemistry and Tissue Hybridization. (2022) (0)
- Abstract P6-03-05: Dual HER2 blockade of an activating driverHER3mutation: A proof of principle study in a metastatic breast cancer patient (2015) (0)
- P1-06-14: Topoisomerase II alpha (Top2a) Protein Expression Is a Predictor for Response to Anthracycline-Based Chemotherapy (ATC-CT): Is It Due to Gene Amplification, HER2−Coamplification or a Summation of Pathways Leading to This Highly Proliferative Phenotype? (2011) (0)
- Mutational signature analysis of primary and metastatic endometrial cancer reveals associations with molecular subtypes and shifts during tumor progression (2019) (0)
- 5175 POSTER Bcl2 Expression Predicts Clinical Outcome to Adjuvant Hormone Therapy and Response to Anthracycline-based Chemotherapy in ER+HER2- Breast Cancer (2011) (0)
- Abstract P2-10-01: The genomic landscape of breast cancer in African American women (2020) (0)
- Abstract P6-06-02: GermlineCDH1mutations in lobular carcinomain situ (2016) (0)
- Atypical lobular hyperplasia (2019) (0)
- Abstract GS2-01: Discovery and characterization of an estrogen bound LncRNA in late-Stage breast cancer (2018) (0)
- Abstract 4258: Benchmarking algorithms for mutation impact prediction using functionally validated missense mutations (2014) (0)
- lesionsbreast pathology: columnar cell (2009) (0)
- Abstract P4-04-05: Molecular subtyping reveals the heterogeneity of metaplastic breast cancers (2013) (0)
- Abstract P5-02-33: Deep learning-based assessment of HER2-low expression on breast cancer H&E digital whole slide images (2023) (0)
- Abstract 1692: Single-cell DNA sequencing from frozen endometrial tumors to address clonal evolution of somatic mutations (2022) (0)
- OP-JNCI190159 107..110 (2020) (0)
- Abstract 3885: Mutational landscape and copy number alterations of mucinous breast carcinoma (2015) (0)
- The Role of BRCA1 and BRCA2 in Anticancer Drug Therapy (2013) (0)
- Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (0)
- O8: Array CGH Using Whole Genome Amplification Of Fresh Frozen And Formalin-Fixed, Paraffin-Embedded Tumour DNA (2005) (0)
- Molecular Genetics of Ductal Carcinoma In Situ and Lobular Carcinoma In Situ (2011) (0)
- REVMUT v0.3.0 (2015) (0)
- Mechanistic and clinical analysis of Sperm associated antigen 5 (SPAG5) as a novel prognostic, predictive, actionable gene in Breast Cancer (BC). (2015) (0)
- Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer (2022) (0)
- 93P An AI-driven computational biomarker from H&E slides recovers cases with low levels of HER2 from immunohistochemically HER2-negative breast cancers (2022) (0)
- 5030 High resolution array Comparative Genomic Hybridization (aCGH) of breast carcinoma identifies Mouse double minutes 4 (Mdm4) as one of the early genetic changes in breast cancer development – Mdm4 is a new independent prognostic and predictive marker (2009) (0)
- Abstract P6-09-01: RAD51B loss-of-function variants confer susceptibility to hereditary breast and ovarian cancers and result in tumors with genomic features of homologous recombination repair defects (2020) (0)
- Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype. (2023) (0)
- Immune and genomic profiling of small cell carcinomas of the ovary hypercalcemic type (2020) (0)
- Abstract P4-08-12: Clinical and Genomic Landscape of Breast Cancers Carrying CCNE1 Amplification (2023) (0)
- Abstract P6-07-04: Distinct repertoires of somatic mutations affecting driver genes in mucinous and neuroendocrine carcinomas of the breast (2016) (0)
- Abstract P2-08-08: Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis (2016) (0)
- Abstract P4-05-06: Host inflammation and breast cancer molecular subtypes: Updated results from a TCGA sub-analysis (2013) (0)
- Phylogenetic Relationship Between Locoregional Recurrences and Distant Metastasis in Breast Cancer (2019) (0)
This paper list is powered by the following services: